A Pseudomonas aeruginosa phage pPA-3099-2aT.2 and its application and preparation

Through Pseudomonas aeruginosa phage pPA-3099-2aT.2, the treatment problem of multidrug-resistant Pseudomonas aeruginosa was solved, effective inhibition and killing of the bacteria was achieved, and new treatment plans and disinfection methods were provided. , has the characteristics of safety and efficiency.

CN116042542BActive Publication Date: 2024-11-26YOUYIBANG BIOTECHNOLOGY (SHANGHAI) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310044165.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-29
Publication Date
2024-11-26
Estimated Expiration
2043-01-29

AI Technical Summary

Technical Problem

The multidrug resistance and wide resistance of Pseudomonas aeruginosa pose great challenges to clinical treatment and has become a global public health issue. It is difficult for existing technologies to effectively inhibit and kill this bacteria.

Method used

A Pseudomonas aeruginosa phage pPA-3099-2aT.2 has a wide host spectrum and a fast latency, which can quickly kill host bacteria, and has good temperature, acid-base tolerance and hydrophilicity, suitable for Prepare drugs to prevent and treat multidrug-resistant Pseudomonas aeruginosa.

Benefits of technology

Pseudomonas aeruginosa phage pPA-3099-2aT.2 has a strong disinfection effect on multidrug-resistant Pseudomonas aeruginosa. It has a short incubation period, small toxic side effects, and high safety. It is suitable for the preparation of prevention and treatment drugs and can effectively inhibit it. and kill infected Pseudomonas aeruginosa, significantly improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116042542B_ABST
    Figure CN116042542B_ABST
Patent Text Reader

Abstract

The present application provides a Pseudomonas aeruginosa phage pPA-3099-2aT.2 and its application and preparation. The taxonomic name of Pseudomonas aeruginosa phage pPA-3099-2aT.2 is Pseudomonas aeruginosa phage pPA‑3099‑ 2aT.2 The phage is deposited in Guangdong Microbiological Culture Collection Center (GDMCC), with the address of 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and the deposit number is GDMCC No: 62850-B1. The phage of the present application can quickly kill the host bacteria in the culture medium, has small toxic side effects, high safety, a wide range of temperature and acid-base tolerance, and good hydrophilicity. It is easy to make a spray and an injection, has a good inhibitory and killing effect on the proliferation of Pseudomonas aeruginosa, and has a good therapeutic and protective effect on animals infected with multidrug-resistant Pseudomonas aeruginosa.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microorganisms, and more specifically, to a Pseudomonas aeruginosa phage and an application and preparation thereof. Background Art

[0002] Pseudomonas aeruginosa ( Pseudomonas aeruginosa , PA), is a non-fermenting, aerobic Gram-negative bacillus of the Pseudomonas family. It is widely present in nature and can tolerate harsh environments. It is highly pathogenic and can cause a variety of diseases such as cystic fibrosis, pneumonia, urinary tract infection, otitis externa, wound infection, bone and joint infection, bacteremia and systemic infection. It is also the main cause of death in patients with cystic fibrosis, and severe infection can endanger the patient's life. The International Federation of Hospital Infection Control monitored 703 intensive care units around the world and found that Pseudomonas aeruginosa is the main pathogen causing nosocomial infection, followed by Acinetobacter baumannii and Klebsiella pneumoniae. According to the 2020 National Bacterial Resistance Monitoring Report, among the clinically isolated bacteria, the number of Pseudomonas aeruginosa isolations ranks third (12.2%). It can be seen that Pseudomonas aeruginosa infection is a problem that cannot be ignored. In recent years, the emergence of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa has brought great challenges to clinical treatment and has also become a global public health issue.

[0003] Bacteriophages are viruses that can infect and kill bacteria. They were discovered by Twort in 1915 and were successfully used to treat bacterial infections in animals and humans in the early 1920s. Phage research in the early 20th century was mostly focused on the treatment of bacterial infections, but this hot research focus gradually weakened with the emergence of antibiotics. In recent years, with the widespread emergence of antibiotic-resistant bacteria, phages have once again become the focus of research. Phages can efficiently and specifically lyse host strains to death and release progeny, and are natural bactericides with high biosafety. The use of phages to curb the spread of drug-resistant bacteria and treat deep bacterial infections such as bone and joints has a very broad application prospect. For example, Karlis Racenis et al. used phage cocktails combined with antibiotics to eradicate Pseudomonas aeruginosa in the proximal femoral bone segment of patients with recurrent multidrug-resistant (MDR) Pseudomonas aeruginosa femoral osteomyelitis, avoiding amputation. T. Ferry et al. provided 21 days of phage therapy for patients with acute kidney injury caused by bacteremia treated with antibiotics. The condition improved and there were no adverse reactions related to phage therapy. At the same time, phages are also an important component of the microecology. They have their own microecology systems in the human and animal intestines, soil environments, and water environments, and play an important role in regulating the functions of the microecology system. Summary of the invention

[0004] In view of the above technical problems, the present invention provides a Pseudomonas aeruginosa phage and its application in inhibiting and killing multi-drug resistant Pseudomonas aeruginosa, aiming to provide a new treatment plan for Pseudomonas aeruginosa infection and a potential new disinfection method for environmental and feed pollution caused by Pseudomonas aeruginosa.

[0005] The present application provides a Pseudomonas aeruginosa phage pPA-3099-2aT.2, taxonomically named Pseudomonas aeruginosa phage pPA-3099-2aT.2, the phage is deposited in Guangdong Microbiological Culture Collection Center (GDMCC), the storage address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and the storage number is: GDMCC No: 62850-B1.

[0006] The present application provides a preparation, comprising the above-mentioned Pseudomonas aeruginosa phage pPA-3099-2aT.2.

[0007] The present application also provides the use of Pseudomonas aeruginosa phage pPA-3099-2aT.2 in the preparation of a preparation for preventing and treating Pseudomonas aeruginosa infection.

[0008] Compared with the prior art, the present invention has the following beneficial effects:

[0009] (1) Pseudomonas aeruginosa phage pPA-3099-2aT.2 is a broad host spectrum phage. This phage has a strong disinfecting effect on 18 strains of Pseudomonas aeruginosa purchased from UniBio (Shanghai) Co., Ltd. (see Table 1 for product numbers). It has a broad antibacterial spectrum and can be used to prepare drugs for the prevention and treatment of multidrug-resistant Pseudomonas aeruginosa.

[0010] (2) The incubation period of Pseudomonas aeruginosa phage pPA-3099-2aT.2 is short (less than 10 minutes), and it can quickly kill the host bacteria in the culture medium. It has low toxicity and side effects, high safety, a wide temperature and acid-base tolerance range, and good hydrophilicity. It can be easily made into sprays and injections, and has a good inhibitory and killing effect on the proliferation of Pseudomonas aeruginosa. It has a good therapeutic and protective effect on animals infected with multidrug-resistant Pseudomonas aeruginosa. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 This is a plaque picture of the Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0012] Figure 2 It is a transmission electron microscope image of the Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0013] Figure 3It is a one-step growth curve diagram of the Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0014] Figure 4 It is a schematic diagram showing the effect of temperature on the activity of the Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0015] Figure 5 It is a schematic diagram showing the effect of pH on the activity of the Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0016] Figure 6 It is a schematic diagram of sterilization in the culture medium of Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0017] Figure 7 It is a schematic diagram of the treatment of greater wax moth larvae infected with Pseudomonas aeruginosa by the Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention.

[0018] The Pseudomonas aeruginosa phage pPA-3099-2aT.2 provided by the present invention has a taxonomic name of Pseudomonas aeruginosa phage pPA-3099-2aT.2, and was deposited in the Guangdong Provincial Microbiological Culture Collection Center (GDMCC) on October 8, 2022, with the deposit number: GDMCC No: 62850-B1; the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. DETAILED DESCRIPTION

[0019] The following examples may enable those skilled in the art to more fully understand the present invention, but are not intended to limit the present invention in any way.

[0020] The strains, reagents and culture media involved in the embodiment are:

[0021] The host bacteria used in the experiment were multidrug-resistant Pseudomonas aeruginosa clinical strains, purchased from Unibond Biotechnology (Shanghai) Co., Ltd., with a product number of MPEB0011222. The Pseudomonas aeruginosa phage pPA-3099-2aT.2 of the present invention was deposited in Guangdong Microbiological Culture Collection Center (GDMCC), with a deposit number of GDMCC No: 62850-B1; the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou.

[0022] MH broth (1 L): Weigh 21.0 g of MH broth, dissolve in 1000 mL of ddH2O, and sterilize under high pressure at 121°C for 20 min.

[0023] 0.7% MH (B) semi-solid medium (1L): weigh 21.0g of MH broth and 7.0g of agar powder, add ddH2O to 1000mL, and sterilize at 121℃ for 20min.

[0024] MH(A) medium (1 L): Weigh 36.5 g of MH(A) medium (Mueller-Hinton Agar), add 1000 mL of ddH2O, sterilize at 121°C for 20 min, cool to 50°C, pour onto a plate, cool and solidify, then invert for later use.

[0025] SM buffer, PBS, DNase I, RNase A, PEG8000, NaOH, HCl, and NaCl were commercially available. Example 1

[0026] Isolation and Purification of Pseudomonas aeruginosa Phage pPA-3099-2aT.2

[0027] The host bacteria 3099-2aT was streaked and inoculated on MH(A) medium. After culturing overnight, a single clone was picked and inoculated into 5 mL of liquid culture medium. After shaking culture at 37°C for 12 h, it was used as the host bacteria culture for later use.

[0028] The samples were collected from sewage from a farm in Tianjin. The sewage samples were centrifuged at 4°C and 8000r for 10 minutes, and the supernatant was filtered with a 0.22μm filter membrane. 1000μL of the filtrate was taken, 100μL of the host bacterial solution was added, and then 5mL of MH (B) medium was added, and the culture was placed in a constant temperature oscillator for 12 hours. The culture was centrifuged at 4°C and 8000r / min for 10 minutes, and the supernatant was filtered with a 0.22μm filter membrane for sterilization to form a stock solution containing phages, i.e., a phage suspension.

[0029] Pipette 100 μL of the above-mentioned spare host bacteria culture into a 10 mL sterile centrifuge tube, pour in 8 mL of preheated semi-solid culture medium, invert and mix well, then pour on a solid plate. After drying, divide the plate into two areas, take 10 μL of the above-mentioned phage suspension and drop it on one side of the plate, and drop the same volume of PBS on the other side as a blank control. After drying naturally, invert and culture in a 37°C incubator for 12 hours, and observe whether there is plaque formation in the phage drop area. If plaques are formed, it proves that phages exist.

[0030] Take another 100μL of the above phage suspension and dilute it 10 times continuously. Take 100μL of the 10-5~10-8 dilutions and mix them with the same volume of host bacterial solution. Let it stand for 10 minutes, add 5~8mL of 0.7% semi-solid MH (B) medium at about 50℃, evenly spread it on the pre-prepared solid MH (A) plate, and observe the growth of plaques after culturing at 37℃ for 12 hours. Pick a single transparent and uniform plaque into a 1000 μLMH (B) EP tube, dilute it to the appropriate concentration, take 100μL of the dilution and make a double-layer plate with the same volume of host bacterial solution. Repeat this 3-5 times to obtain phages with uniform plaque size, store at 4℃ for later use.

[0031] Plaque results Figure 1 As shown, the phage can form clear plaques in agar culture medium with clear and regular edges and a diameter of about 2.3 mm, which is a typical lytic phage. Example 2

[0032] Amplification and Concentration of Pseudomonas aeruginosa Phage pPA-3099-2aT.2

[0033] Take 0.1 mL of the phage storage solution prepared in Example 1 and 0.1 mL of the host bacteria culture prepared in Example 1 in a test tube and act for 15 min, add 10 mL of MH (B) liquid culture medium, culture at 37° C. for 12 h, centrifuge at 4° C. and 8000 r / min for 20 min, take the supernatant, filter with a 0.22 μm filter membrane, and the filtrate is the phage lysate.

[0034] PEG concentration: add DNaseI and RNaseA to the phage lysate to a final concentration of 1 μg / mL, let it stand at room temperature for 30 min, add NaCl to a final concentration of 1 mol / L and place it on ice for 2 h, centrifuge at 4°C, 10,000 rpm / min for 20 min, take the supernatant and add PEG8000 with a final concentration of 10%, place it on ice for 12 h, then centrifuge at 4°C, 10,000 rpm / min for 20 min, carefully discard the supernatant, invert for 5 min to allow the liquid to drain, add 2 mL SM buffer to resuspend the precipitate, add an equal volume of chloroform and gently shake for 30 s, centrifuge at 4°C, 5,000 rpm / min for 15 min to separate the organic phase and the hydrophilic phase, recover the hydrophilic phase containing phage particles, and obtain a concentrated phage suspension. Example 3

[0035] Observation of Pseudomonas aeruginosa phage pPA-3099-2aT.2 by transmission electron microscopy

[0036] The concentrated phage suspension of Example 2 was observed under an electron microscope. The concentrated phage suspension of Example 2 was dropped on a copper sheet and allowed to precipitate naturally for 2 to 3 minutes. Excess liquid was removed with filter paper, and a drop of 2% phosphotungstic acid (PTA, 2% w / v) was added for staining. After drying at room temperature, the suspension was observed under a transmission electron microscope. The results are shown in FIG. Figure 2 The phage pPA-3099-2aT.2 is a muscle-tailed phage with a regular icosahedral head structure, a head diameter of about 76.686 nm, and a tail length of 123.886 nm in the stretched state.

[0037] The applicant named the phage pPA-3099-2aT.2 and deposited it in the Guangdong Microbiological Culture Collection Center (GDMCC), the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, and the deposit number is GDMCC No: 62850-B1. Example 4

[0038] Determination of the One-Step Growth Curve of Pseudomonas aeruginosa Phage pPA-3099-2aT.2

[0039] Mix the reserved host bacteria culture in Example 1 with the reserved phage in Example 1 (the infection multiplicity is about 0.001), incubate at 37°C for 10 minutes, then centrifuge at 10,000 r / min for 1 minute, discard the supernatant, and wash the precipitate twice with MH (B) liquid culture medium. Resuspend the precipitate with 5 mL of preheated MH (B) liquid culture medium, and quickly place it in a 37°C shaker for shaking culture. Starting from 0 min, take 200 μL of culture every 10 minutes, centrifuge at 4°C and 10,000 r / min for 2 minutes to remove bacteria, take the supernatant and dilute it tenfold to the appropriate concentration, and determine the phage titer by the double-layer plate method. Draw a one-step growth curve with the sampling time as the horizontal axis and the logarithm of the phage titer as the vertical axis. The results of the one-step growth curve are shown as follows: Figure 3 As shown, the incubation period of host bacteria infection is less than 10 minutes, and it enters the plateau phase at the 100th minute, with an explosive volume of about 178 PFU / Cell. Example 5

[0040] Temperature and pH tolerance test of Pseudomonas aeruginosa phage pPA-3099-2aT.2

[0041] Take 6 sterile EP tubes, add 1 mL of the phage prepared in Example 1 to each tube, and incubate at -20°C, 4°C, 25°C, 37°C, 50°C, 60°C, and 70°C for 60 min, and then measure the phage titer. Figure 4 As shown: the phage can still maintain high activity at a temperature of -20℃ to 37℃ for 1 hour and can withstand a high temperature of 60℃, but the phage completely loses its activity after incubation at 70℃ for 1 hour.

[0042] Take 7 portions of 100 μL of the phage prepared in Example 1 and put them into MH (B) (900 μL) with pH values ​​of 2, 4, 6, 7, 8, 10, and 12 respectively, and react at 37°C for 1 hour. Then, the titer of the phage after the reaction is determined by the double-layer method. The test results are as follows: Figure 5 As shown: the titer of Pseudomonas aeruginosa phage pPA-3099-2aT.2 changes little in an environment with a pH value of 6 to 10, and the activity remains basically unchanged. After acting in an environment with a pH of 4 for 1 hour, the titer is slightly lower than that in an environment with a pH of 6, and it is completely inactivated after being in an environment with a strong acid of pH 2 and a strong base of pH 12 for 1 hour. Example 6

[0043] Analysis of host spectrum of Pseudomonas aeruginosa phage pPA-3099-2aT.2

[0044] The host spectrum of Pseudomonas aeruginosa phage pPA-3099-2aT.2 was analyzed using 18 strains of Pseudomonas aeruginosa. The above strains are all from Unibond Biotechnology (Shanghai) Co., Ltd., and the product numbers are shown in Table 1. The specific operation is as follows: Take 100μL of the culture solution of 18 strains of bacteria in a 10mL sterile centrifuge tube, add preheated semi-solid culture medium, invert and mix, and pour on a solid plate. After it solidifies, take 10μL of phage solution and drop it on the surface of the plate. Use PBS as a negative control. After drying, invert and culture at 37℃ for 12h. If completely transparent plaques are produced, they are recorded as "+++", obvious transparency is recorded as "++", semi-obvious transparency is recorded as "+", and no plaques are recorded as "-". The results are shown in Table 1. Pseudomonas aeruginosa phage pPA-3099-2aT.2 can not only lyse the multi-drug resistant host bacteria 3099-2aT, but also lyse 8 strains of Pseudomonas aeruginosa, including N1803-4At, N3180-3AT, 3094-2At, 3102-3At, 3103-3At, 3111-1At from human sources and m1308-2Dr from environmental water samples. Table 1 shows the host spectrum of Pseudomonas aeruginosa phage pPA-3099-2aT.2.

[0045] Table 1

[0046] Serial number Part Number Latin name Resistance type Strain host Strain source Fragmentation 1 MPEB0005351 Pseudomonas aeruginosa - Air raid shelter water sample UniBio (Shanghai) Co., Ltd. ++ 2 MPEB0005797 Pseudomonas aeruginosa - Green-cheeked Conure UniBio (Shanghai) Co., Ltd. - 3 MPEB0007097 Pseudomonas aeruginosa - mosquito UniBio (Shanghai) Co., Ltd. ++ 4 MPEB0008347 Pseudomonas aeruginosa - dugout UniBio (Shanghai) Co., Ltd. - 5 MPEB0009683 Pseudomonas aeruginosa - Veiled Chameleon Oral UniBio (Shanghai) Co., Ltd. - 6 MPEB0009685 Pseudomonas aeruginosa - Veiled Chameleon Oral UniBio (Shanghai) Co., Ltd. - 7 MPEB0009689 Pseudomonas aeruginosa - Rhino iguana skin wound UniBio (Shanghai) Co., Ltd. - 8 MPEB0009711 Pseudomonas aeruginosa - Rhino iguana skin wound UniBio (Shanghai) Co., Ltd. - 9 MPEB0009713 Pseudomonas aeruginosa - Rhino iguana skin wound UniBio (Shanghai) Co., Ltd. - 10 MPEB0011411 Pseudomonas aeruginosa Human feces UniBio (Shanghai) Co., Ltd. ++ 11 MPEB0011222 Pseudomonas aeruginosa MDR Severe sputum UniBio (Shanghai) Co., Ltd. +++ 12 MPEB0006283 Pseudomonas aeruginosa - people UniBio (Shanghai) Co., Ltd. - 13 MPEB0008307 Pseudomonas aeruginosa - dugout UniBio (Shanghai) Co., Ltd. - 14 MPEB0009737 Pseudomonas aeruginosa - Yellow-throated Terrapin Skin UniBio (Shanghai) Co., Ltd. - 15 MPEB0011212 Pseudomonas aeruginosa MDR Severe sputum UniBio (Shanghai) Co., Ltd. +++ 16 MPEB0011228 Pseudomonas aeruginosa - Severe sputum UniBio (Shanghai) Co., Ltd. +++ 17 MPEB0011230 Pseudomonas aeruginosa - Severe sputum UniBio (Shanghai) Co., Ltd. +++ 18 MPEB0011242 Pseudomonas aeruginosa - Severe sputum UniBio (Shanghai) Co., Ltd. ++ Example 7

[0047] Bactericidal effect of Pseudomonas aeruginosa phage pPA-3099-2aT.2 in culture medium

[0048] Example 1 Alternative host bacteria 3099-2aT culture adjustment OD 595 to 0.1 (the number of viable bacteria is about 3.8×10 8cfu), and set aside in an ice bath. Take 4 centrifuge tubes, mark the control group, MOI=100, 1, and 0.01, add 9 ml of the culture in the ice bath, add 9 ml of MH(B) to the control group, and add 9 ml of the corresponding phage solution to the experimental group. Quickly divide them into 1.5 ml centrifuge tubes and place them in a 37°C constant temperature shaker for culture. Measure the absorbance of the culture at OD595nm every 3 hours. With time as the horizontal axis and OD as the horizontal axis, the absorbance of the culture at OD595nm is 90%. 595 The value is taken as the vertical axis, and the in vitro inhibition curve is drawn.

[0049] The results of the bacteriophage killing experiment are as follows Figure 6 As shown, the control group (3099-2aT + MHB) had an OD of 595 The value showed an upward trend, and the bacterial count gradually increased, and entered a plateau phase after 9 hours. When phage pPA-3099-2aT.2 was added at different infection multiplicities, the curve trend was roughly the same: in the first 9 hours, OD 595 The value was less than 0.1 and significantly lower than that of the control group, indicating that Pseudomonas aeruginosa 3099-2aT.2 was lysed in large quantities; OD of different infection multiplicity groups after 9 hours 595 The values ​​showed an increasing trend, and the greater the multiplicity of infection, the earlier the value increased, but the values ​​were always lower than those in the control group. Example 8

[0050] Protection experiment of Pseudomonas aeruginosa phage pPA-3099-2aT.2 based on the wax moth larvae model

[0051] The phage protection test was conducted using the larvae of the greater wax moth as a model to evaluate the anti-infection potential of phages. 60 healthy larvae weighing about 250-300 mg were selected and randomly divided into 6 groups, with 10 in each group. They were starved the day before the experiment to reduce their immunity. During the experiment, the larvae were surface disinfected with a cotton swab containing 75% ethanol. The groups were divided according to Table 2, and the corresponding liquids were injected using a microsyringe: the first injection of 10 μL was injected through the left foot of the first tail, and 0.5 hours later, the second injection was injected on the opposite side. After the injection, the larvae were placed in a culture dish and cultured in a dark environment at 37°C (fasting), observed every 3 hours, and the survival rate of the greater wax moth larvae was recorded for 24 hours. (When the greater wax moth larvae did not show any movement under tactile stimulation, they were considered dead.)

[0052] The results are as follows Figure 7 As shown in Figure 2, after SPSS software Kaplan-Meier analysis, the survival rate of G. mellonella larvae that were infected with Pseudomonas aeruginosa 3099-2aT.2 but not injected with phage was only 40% at 18h after infection, and only 10% at 21h; while the survival rate of G. mellonella larvae in the fourth group injected with phage at MOI=100 was 100% at 24h, which was significantly higher than that in the third group (P <0.01), indicating that the phage has a significant protective effect on the larvae of G. mellonella. At the same time, the survival rate of the second group injected with saline and phage was 100% at 24h, proving that phage injection is safe for G. mellonella larvae.

[0053] Table 2

[0054] serial number Group First injection Second injection 1 Negative control group Normal saline Normal saline 2 Phage safety control group Normal saline Bacteriophage 3 Infection group Normal saline bacteria 4 Phage therapy group bacteria MOI=100 5 Phage therapy group bacteria MOI=1 6 Phage therapy group bacteria MOI=0.01 Example 9

[0055] Detection of environmental bactericidal effect of Pseudomonas aeruginosa phage pPA-3099-2aT.2

[0056] A 50cm×40cm white disk was divided into a 20cm×20cm test area and two 10cm×10cm negative / positive controls, and the above areas were divided into 1cm 2 The small squares were sterilized and set aside for use. The Pseudomonas aeruginosa 3099-2aT.2 cultured to the logarithmic phase was adjusted to OD 595 After centrifugation, wash with saline and resuspend for later use. Spray 2 mL 3.8×10 8 After the bacterial suspension, 2 mL of pPA-3099-2aT.2 phage suspension with MOI=100 was evenly sprayed. 1 mL of physiological saline and 3.8×10 8 The above tests were all performed in a biosafety cabinet. Three 1 cm2 samples were randomly selected from the test area and the negative / positive control area at 1 h, 2 h, and 6 h. 2 The small squares were swabbed to collect bacteria and the live bacteria counts were performed.

[0057] The results showed that the bacteriophage pPA-3099-2aT.2 had a good environmental bactericidal effect. After 1 hour, the number of live bacteria in the sampling areas of the test area and the negative control area was 0, and the average number of live bacteria remaining in the sampling area of ​​the positive control area was 1.8×10 2 CFU, the experimental area and the positive control area have a very significant difference ( P <0.01). After 2h and 6h, only one sampling area in the test area had 1×10 1 The residual CFU bacteria indicated that bacteriophage pPA-3099-2aT.2 had strong bactericidal ability in the environment.

[0058] In summary, Pseudomonas aeruginosa phage pPA-3099-2aT.2 has good application prospects in the prevention, control and treatment of Pseudomonas aeruginosa infections and environmental sterilization.

[0059] It should be understood by those skilled in the art that the above embodiments are merely exemplary embodiments and that various changes, substitutions and alterations may be made without departing from the spirit and scope of the present invention.

Claims

1. A Pseudomonas aeruginosa phage ( Pseudomonas aeruginosa phage )pPA-3099-2aT.2, taxonomically named Pseudomonas aeruginosa phage pPA-3099-2aT.2 The phage was deposited in Guangdong Microbiological Culture Collection Center (GDMCC), with the address: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou, with the deposit number: GDMCC No: 62850-B1.

2. A preparation comprising the Pseudomonas aeruginosa phage pPA-3099-2aT.2 as described in claim 1.

3. Use of the Pseudomonas aeruginosa phage pPA-3099-2aT.2 as claimed in claim 1 in the preparation of a preparation for preventing and treating Pseudomonas aeruginosa infection.